Skip to main content

Holiday schedule

Quest Diagnostics Patient Service Centers will be closed on Monday, September 7th, 2026 in observance of the Labor Day Holiday.  Have a healthy, happy holiday.

Hide
Quest Diagnostics

Toxic Epidermal Necrolysis-Like Linear IgA Bullous Dermatosis as a Manifestation of Multiple Drug Hypersensitivity in the Setting of Drug Reaction With Eosinophilia and Systemic Symptoms

Toxic Epidermal Necrolysis-Like Linear IgA Bullous Dermatosis as a Manifestation of Multiple Drug Hypersensitivity in the Setting of Drug Reaction With Eosinophilia and Systemic Symptoms

Authors: Stratman S, Zhou L, Kim RH, Phelps RG, Glickman J, Mikhaylov D, Wu J, El-Kashlan N, Rivera-Oyola R, Adalsteinsson JA, Levoska MA, Gulati N

Citation: JAAD Case Rep. 2024 Apr 27;49:36-39. doi: 10.1016/j.jdcr.2024.04.028. eCollection 2024 Jul.

Specialties: Dermatology, Immunology, Toxicology

Disclaimer: One or more of the authors of this publication were employed at the time by DermPath Diagnostics, a subsidiary of Quest Diagnostics.

Related content

Publication
Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: Case report
Publication
Acquired Perforating Dermatosis Induced by PD-1 Inhibitor: A Case Report

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.